Phase 4
N=240
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
Pain
Bottom Line
View on ClinicalTrials.gov: NCT02078492 ↗Enrolled (actual)
240
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Pain Score at 30 Minutes — 5.14; 5.05; 4.81 pain score
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- 10 mg of Ketorolac (Drug); 15 mg of Ketorolac (Drug); 30 mg of Ketorolac (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Antonios Likourezos
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score at 30 Minutes |
5.14; 5.05; 4.81 | — |
| SECONDARY Adverse Effect of Dizziness |
14; 16; 12 | — |
| SECONDARY Adverse Effect of Nausea |
9; 11; 8 | — |
| SECONDARY Adverse Effect of Headache |
8; 2; 3 | .783 |
Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
Eligibility Criteria
Inclusion Criteria
Severe flank and abdominal pain, severe musculoskeletal pain (traumatic and non-traumatic in origin), headache, dental pain.
Exclusion Criteria
Age >65, Active Peptic Ulcer disease, Acute Gastrointestinal Hemorrhage, Known Hx of Renal or Hepatic insufficiency, Hx of allergies to NSAIDS.
Data sourced from ClinicalTrials.gov (NCT02078492). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.